Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, Wong CH, Tang Y, Zhu F, Wilner KD, Wu YL. Cheng Y, et al. Among authors: du y. Lung Cancer. 2021 Apr;154:176-185. doi: 10.1016/j.lungcan.2021.02.025. Epub 2021 Feb 23. Lung Cancer. 2021. PMID: 33721611 Free article. Clinical Trial.
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Zhu Y, Du Y, Liu H, Ma T, Shen Y, Pan Y. Zhu Y, et al. Among authors: du y. Thorac Cancer. 2016 Nov;7(6):663-669. doi: 10.1111/1759-7714.12384. Epub 2016 Aug 24. Thorac Cancer. 2016. PMID: 27755796 Free PMC article. Clinical Trial.
Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y, Cao Q, Jiang C, Liang H, Ning Z, Ji C, Wang J, Zhou C, Jiang Z, Yu C, Li L, Zhao Y, Xu Y, Xu T, Hu W, Wang D, Cheng H, Wang G, Zhou J, Wang S, Zhang Y, Hu Z, Li X, Lu D, Zhang J, Xie H, Sun G. Du Y, et al. Cancer Med. 2020 Jul;9(14):5008-5014. doi: 10.1002/cam4.3105. Epub 2020 May 22. Cancer Med. 2020. PMID: 32441892 Free PMC article.
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Cui J, Li Y, Zhao H, Fang J, Xue J, Hu C, Sun P, Du Y, Zhou H, Wang S, Zhang W. Zhou C, et al. Among authors: du y. J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25. J Thorac Oncol. 2021. PMID: 34048947 Free article. Clinical Trial.
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Lu S, Zhou Q, Liu X, Du Y, Fan Y, Cheng Y, Fang J, Lu Y, Huang C, Zhou J, Song Y, Wang K, Pan H, Yang N, Li J, Chen G, Chang J, Cui J, Liu Z, Bai C, Zhang H, Zhao H, Zhang K, Peltz G, Li H, Wu YL. Lu S, et al. Among authors: du y. J Thorac Oncol. 2022 Jun;17(6):816-826. doi: 10.1016/j.jtho.2022.02.014. Epub 2022 Mar 17. J Thorac Oncol. 2022. PMID: 35307611 Free article. Clinical Trial.
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).
Liu SM, Yan HH, Wei XW, Lu C, Dong XR, Du Y, Cui JW, Chen Y, Ma R, Wang BH, Zhou Z, Cang SD, Yang JJ, Tu HY, Zhang XC, Zhong WZ, Zhou Q, Wu YL. Liu SM, et al. Among authors: du y. Clin Lung Cancer. 2022 Nov;23(7):e395-e399. doi: 10.1016/j.cllc.2022.05.009. Epub 2022 May 11. Clin Lung Cancer. 2022. PMID: 35659479 Free article. Clinical Trial.
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, Li W, Li R, Wang X, Lu Z, Wang D, Wu X, Liu Z, Xing L, Mao Y, Liu C, Zeng A, Niu H, Du Y, Sun Y, Pan Y, Hu Y, Zhang X, Chen X, Ma Z, Li N, Zhang J, Zhao M, Li X, Ye F, Li M, Yu G, Zhang X, Min J, Han D, Li J, Zhou C. Xiong A, et al. Among authors: du y. J Thorac Oncol. 2022 Oct;17(10):1216-1226. doi: 10.1016/j.jtho.2022.06.013. Epub 2022 Jul 5. J Thorac Oncol. 2022. PMID: 35798241 Free article. Clinical Trial.
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Among authors: du y. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.
16,927 results
You have reached the last available page of results. Please see the User Guide for more information.